With their first technology platform company, Procorde , the founders have initiated most of the current projects. During this period, cooperations with large enterprises (e.g. Aventis) have been carried out successfully.
Starting 2007, relevant funding of the successor company Corimmun allowed further clinical development of the most promising drugs. In addition, the founding team succeeded in the acquisition of award-winning “GoBio” projects of the Federal Ministry of Research and Technology (BMBF) and in the participation in “m4”, BMBF’s biotechnology cluster. In June 2012, Corimmun GmbH was sold to Janssen-CILAG GmbH, Neuss, a subsidiary of Johnson + Johnson, New Brunswick, NJ, USA – a price of 100 million USD was paid subsequently, and further milestone-dependent payments and royalties were agreed.
During this transaction, all rights on COR-1 were transferred to Janssen-CILAG – the remaining projects have been pursued under the company name advanceCOR.
The further clinical development of COR-1 is currently being organized by the University of Würzburg, Germany, which still holds the proprietary rights on the patents. An additional phase IIb study is currently being prepared at the German Comprehensive Heart Failure Centre (EudraCT 2015-002010-68)